Sab Biotherapeutics, Inc. · NASDAQ:SABS
Sab Biotherapeutics — Large Animal Genetic Engineering Summit, June 2022
23 slides from Sab Biotherapeutics's conference presentation, Jun 7, 2022
Slide 1: Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutic
Large Animal Genetic Engineering Summit, June 2022 © 2022 SAB BIOTHERAPEUTICS, INC. – CONFIDENTIAL Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutic
Slide 2: Forward Looking Statements
Forward Looking Statements 2 The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (SAB) and is general background information about SAB’s activities current as of the date of this presentation. This information is given in summary form and is not intended to be complete.
Slide 3: Novel DiversitAb Platform for Developing Highly-Differentiated Immunotherapies
Novel DiversitAb™ Platform for Developing Highly-Differentiated Immunotherapies Vertical integration enables rapid, scalable development of multi-targeted products Robust, growing clinical-stage pipeline spanning multiple therapeutic areas Established proof-of-concept through US Government funded pr
Slide 4: DiversitAb Proprietary Platform Technology
DiversitAb™ Proprietary Platform Technology © 2022 SAB BIOTHERAPEUTICS, INC. – CONFIDENTIAL
Slide 5: A Natural Way to Produce Human Polyclonal Antibodies
Only transgenic animal that carries the entire human immunoglobulin (Ig) heavy and light (κ) chain loci. HAC is subject to mitosis along with the other 46 chromsomes. HAC present in the Tc Bovine allows for the highest production of human antibody repertoire most similar to humans. Tc Bovine Tc Bovi
Slide 6: Human Antibody Production in Bovine B-Cell
Human Antibody Production in Bovine B-Cell bIg Bovine chromosomes X X Bovine DNA-binding proteins Tc Bovine B-cells Remove species-incompatibility in protein-protein interaction Remove species-incompatibility in protein-DNA interaction HAC mRNA mRNA Human Bovine Chimeric IgM on B-Cell Receptor Fully
Slide 7: B-Cells Produce Anti-Target Fully-Human Polyclonal Antibodies
B-Cells Produce Anti-Target Fully-Human Polyclonal Antibodies Hyperimmunization Multiple immunizations drive titers to extremely high levels with exceptional avidity maturation and potency B-Cells Produce Human Antibodies Natural and somatic mutation drives very high-level B-cell clone avidity matur
Slide 8: Polyclonals: Broader Spectrum Efficacy
FDA: CENTER FOR DRUG EVALUATION & RESEARCH (CDER) FDA: CENTER FOR BIOLOGICS EVALUATION & RESEARCH (CBER) pAbs TARGET Monoclonal Approach Highly-targeted with specific activity Iterative Ab identification and selection process Selected and cloned in vitro May promote escape mutants via selective pres
Slide 9: Adaptive & Cross Reactive to Mutating Strains
B/Florida/04/2006 Challenge strain SOURCE: NEXTFLU AT HTTPS://NEXTFLU.ORG/VIC/12Y/ Antibodies produced to B/Phuket/3073/2013 protected against B/Florida/04/2006 2006 2017 B/Phuket/3073/2013 Vaccination strain Highly-Mutational Influenza Virus BYAM PHYLOGENIC TREE 100% Protection at All Dose Levels i
Slide 10: Consistent, Replicable Platform In Vivo Efficacy Across Broad Range of Targets
Consistent, Replicable Platform In Vivo Efficacy Demonstrated Across a Broad Range Targets TARGET EFFICACY MODEL(S) COLLABORATORS Anthrax 100% mouse (lethal) Food and Drug Administration Alphaviruses 100% 100% mouse (lethal aerosol) non-human primate (viral clearance) Naval Medical Research Center,
Slide 11: Human Clinical Trial Experience
CLINICAL TRIAL INDICATION COLLABORATORS Phase 1b Mycoplasma hominis Brigham and Women's Hospital, Harvard Phase 1 MERS-CoV Naval Medical Research Center; NIH NIAID Phase 1 Type A and B Influenza Naval Medical Research Center; University of South Dakota Phase 2a Type A and B Influenza Naval Medical R
Slide 12: SAB-185 Anti-SARS-CoV2
Yew BIOTHERAPEUTICS SAB-185 Anti-SARS-CoV2
Slide 13: SAB-185: Specifically Targeted Human Immune Response
SAB-185: Specifically Targeted Human Immune Response Spike Glycoprotein Diversity of antibodies and uniquely combinatorial paratopes drives effector functions including antibody and complement dependent cellular cytotoxicity Multiple blocking and neutralizing antibody species bind to single epitope
Slide 14: Addresses Escape Mutants: SAB-185 Superior to Monoclonal Antibody
Addresses Escape Mutants: SAB-185 Superior to Monoclonal Antibody 14 Selection for VSV-SARS-CoV-2 Wild Type Escape Mutation WASHINGTON UNIVERSITY SCHOOL OF MEDICINE–ST. LOUIS; 15 JAN 2021 Escape Mutants No Escape Mutants SAB-185 Targeted High-Potency Polyclonal Mixture Monoclonal Ab LOT 1 LOT 5 LOT
Slide 15: Mutational Drift and Shift of COVID Variants
Mutational Drift and Shift of COVID Variants x Haseltine W. Birth Of The Omicron Family: BA.1, BA.2, BA.3. Each As Different As Alpha Is From Delta. Online Forbes Article BA.1 BA.2 BA.3 © 2022 SAB BIOTHERAPEUTICS, INC. – CONFIDENTIAL
Slide 16: SAB-185 Provides 100% Protection Against Delta and Omicron in Hamster Model
SAB-185 Provides 100% protection against Delta and Omicron in an in-vivo hACE2 Hamster model Note: Control demonstrated 100% mortality in the ACE2 Hamster Model against Delta Note: Control demonstrated 0% mortality in the ACE2 Hamster Model against Omicron PERFOMRED BY WILLIAM KLIMSTRA’s LAB AT UNIV
Slide 17: NIH ACTIV-2 Trial Confirms SAB-185 Met Virology Endpoints for Phase 3
Phase 2 Data from NIH ACTIV-2 Trial Confirms SAB-185 Met Virology Endpoints for Graduation to Phase 3 * The choice of 0.6 for this Bayesian probability indicates that there is a 3 to 2 odds of the agent being better than placebo by the desired amount (≥0.5 log10 /ml) for the outcome measure. INTERIM
Slide 18: Robust Pipeline with Broad Therapeutic Reach
Robust Pipeline with Broad Therapeutic Reach Ongoing discovery programs in oncology, autoimmune, infectious and idiopathic diseases Government-funded clinical-stage program in Middle East Respiratory Syndrome (MERS) coronavirus SAB-176 SEASONAL INFLUENZA SAB-185 COVID-19 (USG FUNDED) SAB-142 SAB-142
Slide 19: Tc Goats - Expanding The Human Immunotherapeutic Platform
Tc Goats™ - Expanding The Human Immunotherapeutic Platform for Personalized Medicine
Slide 20: Genetic Engineering Science Applied Across SAB Capra
Genetic Engineering Science Applied Across SAB Capra, LLC. is a wholly-owned subsidiary of SAB Biotherapeutics, Inc. Advancing novel antibody production platform leveraging transgenic goats Functionality of the HAC proven in a second species (ruminant ungulate) Generated H7N9-specific human polyclon
Slide 21: Demonstrated Fully Human IgG in Tc Goat
Demonstrated Fully Human IgG in Tc Goat 21 Human IgG in Tc Capra Kids © 2022 SAB BIOTHERAPEUTICS, INC. – CONFIDENTIAL
Slide 22: Positioned for Personalized Medicine
High-dose therapy resulted in improved clinical parameters associated with reduced M. hominis burden following two subsequent infections JARED N SILVER, CAMERON D ASHBAUGH, JACOB J MILES, HUA WU, GREGORY T MARECKI, JOYCE K HWANG, JIN-AN JIAO, MARK ABRAMS, EDDIE J SULLIVAN, DUANE R WESEMANN, DEPLOYME
Slide 23: Advancing the Tc Platform for Continued Advancement of Human Health
Advancing the Tc Platform for Continued Advancement of Human Health Developing targeted human polyclonal antibodies for use in personalized medicine Tc Goat platform production ready for producing diagnostics and testing reagent applications. Accommodating smaller volume markets, lower cost of devel
SAB Biotherapeutics — Large Animal Genetic Engineering Summit, June 2022 on 6ix